Results 261 to 270 of about 2,934,766 (329)

Fasting as Medicine: Mitochondrial and Endothelial Rejuvenation in Vascular Aging

Aging Cell, Volume 25, Issue 2, February 2026.
Aging impairs cerebrovascular health by driving mitochondrial dysfunction, oxidative stress, endothelial failure, and neurovascular uncoupling, leading to BBB breakdown and cognitive decline. In contrast, time‐restricted feeding/eating counteracts these mechanisms by restoring mitochondrial function, activating adaptive nutrient‐sensing pathways ...
Madison Milan, Eva Troyano‐Rodriguez, Jennifer Ihuoma, Sharon Negri, Rakesh Rudraboina, Aleksandra Kosmider, Shantipriya Awasthi, Priya Balasubramanian, Shannon Conley, Andriy Yabluchanskiy, Anna Csiszar, Zoltan Ungvari, Rafael de Cabo, Stefano Tarantini   +13 more
wiley   +1 more source

HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients. [PDF]

Trends Mol Med
Mozzetta C, Sartorelli V, Steinkuhler C, Puri PL.   +3 more
europepmc   +1 more source

From Genomic and Epigenomic Maps to Medicines in Adult T‐Cell Leukemia/Lymphoma

Cancer Science, Volume 117, Issue 2, Page 289-296, February 2026.
ABSTRACT Adult T‐cell leukemia/lymphoma (ATL) is an aggressive and refractory hematologic malignancy that is caused by human T‐cell leukemia virus type‐1 (HTLV‐1) retrovirus. ATL results from a combination of viral latency and the accumulation of abnormalities throughout the genome, epigenome, transcriptome, and signaling pathways.
Kako Suzuki, Makoto Yamagishi
wiley   +1 more source

NF‐κB Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor‐Resistant Cutaneous T‐Cell Lymphoma

Cancer Science, Volume 117, Issue 2, Page 407-417, February 2026.
We identified a novel mechanism of resistance to histone deacetylase inhibitors (HDACi) in cutaneous T‐cell lymphoma (CTCL), mediated by NF‐κB activation. This finding highlights NF‐κB as a potential therapeutic target for overcoming HDACi resistance in CTCL.
Yuto Takahashi, Akihiro Kitadate, Sayaka Iwama, Wataru Kuroki, Ko Abe, Masahiro Yamada, Sho Ikeda, Hiroyuki Tagawa, Hideki Wakui, Masaki Hikida, Naoto Takahashi   +10 more
wiley   +1 more source

Syntheses of LSD1/HDAC Inhibitors with Demonstrated Efficacy against Colorectal Cancer: In Vitro and In Vivo Studies Including Patient-Derived Organoids. [PDF]

J Med Chem
Chou PY, Lai MJ, Tsai KK, Cheng LH, Wu YW, Chen MC, Pan SL, Ho HO, Nepali K, Liou JP.   +9 more
europepmc   +1 more source

Importance of SUMOylation Consensus Sequence of MAFK in Regulating EMT, Tumor Growth, Stemness, and Drug Resistance

Cancer Science, Volume 117, Issue 2, Page 445-455, February 2026.
In this study, we focused on SUMOylation, a posttranslational modification, and investigated the importance of its consensus sequence in MAFK. We demonstrated that the non‐SUMOylation mimic mutant MAFK (EA) impairs MAFK‐induced EMT, cellular migration and invasion, tumor and sphere formation, acquisition of stem‐like properties, and drug resistance ...
Thuy Linh Dang Cao, Yukari Okita, Reon Yahatabara, Manar A. Elhinnawi, Nuriza Ulul Azmi, Thanasis Poullikkas, Hozumi Motohashi, Mitsuyasu Kato   +7 more
wiley   +1 more source

Trichostatin A Sensitizes Tumor Cells to Apoptosis Induced by Soluble Trimeric TRAIL‐Expressing Human Mesenchymal Stromal Cells

Cancer Science, Volume 117, Issue 2, Page 456-467, February 2026.
Human mesenchymal stromal cells (MSCs) were engineered to secrete an isoleucine‐zippered soluble trimeric TRAIL (SCZT) and evaluated with trichostatin A (TSA) to overcome TRAIL resistance. TSA upregulated DR5 and amplified caspase‐8–dependent apoptosis in vitro; in vivo, tumor‐homing MSCs combined with TSA suppressed the growth of both TRAIL‐sensitive ...
Ryosuke Uchibori, Ken Ohmine, Keiya Ozawa   +2 more
wiley   +1 more source

In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF^V600E lung adenocarcinoma. [PDF]

Cell Rep Med
Nokin MJ, Darbo E, Richard E, San José S, de Hita S, Prouzet-Mauleon V, Turcq B, Gerardelli L, Crake R, Velasco V, Koopmansch B, Lambert F, Xue JY, Sang B, Horne J, Ziemons E, Villanueva A, Blomme A, Herfs M, Cataldo D, Calvayrac O, Porporato P, Nadal E, Lito P, Jänne PA, Ricciuti B, Awad MM, Ambrogio C, Santamaría D, Bolero Consortium.   +29 more
europepmc   +1 more source

Pulmonary Vascular Endothelial Cells in Lung Diseases: Mechanisms, Therapeutic Strategies, and Future Directions

Cell Proliferation, Volume 59, Issue 2, February 2026.
The pathogenic mechanisms of pulmonary vascular endothelial cells (VECs) in lung diseases and their multimodal therapeutic strategies. ABSTRACT Pulmonary vascular endothelial cells (VECs) are essential for the normal function of the lung, through maintaining vascular barrier integrity, regulating blood flow, and participating in inflammatory responses ...
Qianyue Liu, Hongshuai Zheng, Jing Liu, Ming Gao, Faquan Lin, Lin Liao   +5 more
wiley   +1 more source